Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 402 participants.

Also called NCT01396395

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 402 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01396395
Other papers using this trial's data
  • Oral nicorandil reduces ischemic attacks in patients with stable angina: A prospective, multicenter, open-label, randomized, controlled study International journal of cardiology, 2016-12-01 DOI, PubMed 27657471

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01396395. Randomized; no masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2016-04-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina
Acronym
SIGMART
Condition
Stable Angina
Condition
Coronary Disease
Intervention (Drug)
Nicorandil
Intervention (Drug)
Standard Treatment
Lead sponsor
Merck KGaA, Darmstadt, Germany (class: industry)
Collaborator
Merck Serono Co., Ltd., China (class: industry)

Record details

Record id
cardio:ct-nct01396395
Content hash
18d0692890ea86a04a1b6fe64e466580c6083106ef7cfac7bdd87c5dcfc3603b